SAMRATPHPharmaceuticals
Samrat Pharmachem Ltd — Cash Flow Statement
₹194.95
-7.93%
Samrat Pharmachem Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -10.60 Cr | 8.75 Cr | -10.90 Cr | 16.20 Cr | — |
| Capital Expenditure | -0.51 Cr | -0.67 Cr | -1.46 Cr | -1.28 Cr | — |
| End Cash Position | 0.05 Cr | 9.67 Cr | 11.86 Cr | 14.71 Cr | — |
| Beginning Cash Position | 9.67 Cr | 11.86 Cr | 14.71 Cr | 0.24 Cr | — |
| Changes In Cash | -9.62 Cr | -2.19 Cr | -2.84 Cr | 14.46 Cr | — |
| Financing Cash Flow | 0.48 Cr | -11.20 Cr | 9.60 Cr | -1.95 Cr | — |
| Interest Paid Cff | -0.67 Cr | -0.69 Cr | -1.23 Cr | -0.67 Cr | — |
| Cash Dividends Paid | -0.31 Cr | -0.31 Cr | -0.31 Cr | — | — |
| Net Issuance Payments Of Debt | 1.46 Cr | -10.20 Cr | 11.14 Cr | -1.27 Cr | — |
| Net Short Term Debt Issuance | 1.46 Cr | -10.20 Cr | 11.14 Cr | -1.27 Cr | — |
| Investing Cash Flow | -49000.00 | -0.41 Cr | -3.00 Cr | -1.06 Cr | — |
| Interest Received Cfi | 0.34 Cr | 0.28 Cr | 0.18 Cr | 0.14 Cr | — |
| Dividends Received Cfi | 0.03 Cr | 0.02 Cr | 0.02 Cr | 0.00 | — |
| Net Investment Purchase And Sale | 0.13 Cr | -0.06 Cr | -1.84 Cr | -15000.00 | — |
| Sale Of Investment | 41.88 Cr | 30.47 Cr | 6.68 Cr | 8.52 Cr | — |
| Purchase Of Investment | -41.75 Cr | -30.53 Cr | -8.52 Cr | -8.52 Cr | — |
| Net PPE Purchase And Sale | -0.51 Cr | -0.65 Cr | -1.36 Cr | -1.20 Cr | — |
| Purchase Of PPE | -0.51 Cr | -0.67 Cr | -1.46 Cr | -1.28 Cr | — |
| Operating Cash Flow | -10.09 Cr | 9.41 Cr | -9.44 Cr | 17.47 Cr | — |
| Taxes Refund Paid | -1.45 Cr | -2.97 Cr | -9.50 Cr | -1.53 Cr | — |
| Change In Working Capital | -19.17 Cr | 9.83 Cr | -24.12 Cr | -5.78 Cr | — |
| Change In Other Current Liabilities | -0.14 Cr | -0.21 Cr | -0.40 Cr | 0.85 Cr | — |
| Change In Other Current Assets | -5.37 Cr | 50000.00 | -3.99 Cr | -0.26 Cr | — |
| Change In Payable | -9.11 Cr | 15.79 Cr | 8.49 Cr | 5.73 Cr | — |
| Change In Inventory | -17.33 Cr | 11.85 Cr | -20.11 Cr | -1.02 Cr | — |
| Change In Receivables | 12.74 Cr | -17.61 Cr | -8.10 Cr | -11.09 Cr | — |
| Other Non Cash Items | 0.33 Cr | 0.41 Cr | 1.05 Cr | 0.55 Cr | — |
| Depreciation And Amortization | 0.65 Cr | 0.65 Cr | 0.64 Cr | 0.59 Cr | — |
| Depreciation | 0.65 Cr | 0.65 Cr | 0.64 Cr | 0.59 Cr | — |
| Gain Loss On Investment Securities | -0.43 Cr | -1.01 Cr | -0.04 Cr | -75000.00 | — |
| Gain Loss On Sale Of PPE | 0.10 Cr | -0.02 Cr | 0.00 | 0.02 Cr | — |
| Net Income From Continuing Operations | 9.89 Cr | 2.52 Cr | 22.53 Cr | 23.60 Cr | — |
| Net Long Term Debt Issuance | — | 0.00 | 0.00 | 0.00 | -0.31 Cr |
| Sale Of PPE | — | 0.02 Cr | 0.10 Cr | 0.08 Cr | 1.08 Cr |
| Amortization Cash Flow | — | 9000.00 | 9000.00 | — | — |
| Provisionand Write Offof Assets | — | — | 0.00 | 0.02 Cr | -14000.00 |
| Issuance Of Capital Stock | — | — | — | 0.00 | 0.00 |
| Other Cash Adjustment Outside Changein Cash | — | — | — | -1000.00 | -1000.00 |
| Net Other Financing Charges | — | — | — | 1000.00 | — |
| Net Common Stock Issuance | — | — | — | 0.00 | 0.00 |
| Common Stock Issuance | — | — | — | 0.00 | 0.00 |
| Net Other Investing Changes | — | — | — | 1000.00 | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Samrat Pharmachem Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.